KRas inhibitors

A compound of the formula:

• wherein:
• A is —C(H)— or —N—;
• Z is —C(R3c)- or —N—;
• G is —C(R3b)- or —N—;
• R is H;
• R2 is H, halogen, or methyl;
• R3b, and R3c are each independently H, halogen, or methyl;
• R4 is a N-linked cyclic amine,
• wherein the N-linked cyclic amine is a N-linked:
• i. azetidine substituted with R4a and R4b;
• or
• ii. pyrrolidine, piperidine, piperazine, or morpholine, each of which is optionally bridged by a C1-3 alkylene, and each of which is optionally substituted with one or more halogen;
• hydroxyl;
• —NR6aR6a;
• (1-methylpiperidin-4-yl)oxy;
• C1-3 alkoxy optionally substituted with-NR6aR6a;
• C1-3 alkyl optionally substituted with one or more halogen, —NR6aR6a or hydroxyl;
• an imidazole optionally substituted with a methyl;
• a monocyclic ring selected from azetidine, piperidine, piperazine, morpholine, oxazepane, or diazepane;
• a bicycle selected from hexahydro-1H-furo[3,4-c]pyrrole, octahydropyrrolo[3,4-c]pyrrole, or octahydropyrrolo[1,2-a]pyrazine;
• or a spirocycle selected from 4,7-diazaspiro[2.5]octane, 2-oxa-7-azaspiro[3.5] nonane, 2,6-diazaspiro[3.4]octane, or 2-azaspiro[3.3]heptane;
• wherein the monocyclic ring is optionally bridged by a C1-3 alkylene, and can optionally be substituted with one or more halogen, hydroxyl, -CN, C1-3 alkoxy, —NR10R10, cyclopropyl, oxetane, -CO-C1-3 alkyl, or a C1-3 alkyl optionally substituted with hydroxyl, C1-3 alkoxy, —NR10R10, halogen, or -CF3;
• and wherein the bicyclo or spirocyclo is each optionally substituted with a methyl or a halogen;
• R4a is NR4R4d, cyclopropyl, azetidine, pyrrolidine, piperidine, piperazine, morpholine or imidazole, wherein the cyclopropyl, azetidine, pyrrolidine, piperidine, piperazine, or morpholine is optionally substituted with halogen, hydroxyl, C1-3 alkoxy or —NR6aR6a;
• R4b is H, hydroxyl, or C1-3 alkyl;
• R4c is independently cyclopropyl or oxetane;
• R4a is independently C1-3 alkyl;
• each R6a is independently H, trideuteromethyl, a C3-5 cycloalkyl, a N-methyl pyrrolidine, tetrahydrofuran, tetrahydropyran, bicyclo[1.1.1]pentan-1-yl, bicyclo[1.1.1]pentan-1-ol, or a C1-3 alkyl optionally substituted with one or more deuterium, hydroxyl, methyl, methoxy, halogen, cyclopropyl, oxetane, tetrahydrofuran, tetrahydropyran, —CO-NHMe, or -CO-NH2, wherein the C3-5 cycloalkyl is optionally substituted with one or more hydroxyl or methyl;
• R10 is H or C1-3 alkyl optionally substituted with one or more deuterium;
• or a pharmaceutically acceptable salt thereof.